Northstar Neuroscience of Seattle said the U.S. Food and Drug Administration gave conditional approval to a new clinical study of its brain-stimulation therapy for depression.

Share story

Northstar Neuroscience said Tuesday that the U.S. Food and Drug Administration granted conditional approval to a new clinical study of its depression therapy.

The Seattle-based biomedical company will begin enrolling patients in the study this quarter and expects preliminary results in the second half of 2009.

The company seeks to treat depression stimulating the outermost layer of the brain with electrodes.